CSBR: 59% | Champions Oncology shares are trading higher after the company reported better-than-expected Q1 financial results. Also, Craig-Hallum upgraded the stock from Hold to Buy and maintained its $6 price target.
NTGR: 31% | NETGEAR shares are trading higher after the company disclosed a settlement agreement with TP-Link Systems and raised its Q3 revenue guidance.
FULC: -74% | Fulcrum Therapeutics' Phase 3 REACH Trial Of Losmapimod In Facioscapulohumeral Muscular Dystrophy Did Not Achieve Its Primary Endpoint Of Change From Baseline In Relative Surface Area With Losmapimod Compared To Placebo. In Addition, Secondary Endpoints Did Not Achieve Nominal Statistical Significance
